Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an update.
Shanghai Henlius Biotech, Inc. has announced the dosing of the first patient in an international multicenter phase 1 clinical study of its Ipilimumab biosimilar, HLX13, for treating unresectable hepatocellular carcinoma (HCC) in mainland China. This study aims to evaluate the pharmacokinetics, safety, efficacy, and immunogenicity of HLX13 compared to the reference product YERVOY, with the potential to impact the company’s market positioning in the oncology sector significantly.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$66.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development of biosimilar drugs. The company specializes in creating monoclonal antibody injections for various cancers, including melanoma, renal cell carcinoma, and hepatocellular carcinoma, among others. It has a market focus on developing treatments that enhance immune responses to target tumors.
Average Trading Volume: 1,562,402
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.44B
See more insights into 2696 stock on TipRanks’ Stock Analysis page.